Baseline Investigations for Secukinumab in Pediatric Psoriasis
Your current pre-treatment workup is comprehensive and appropriate—no additional mandatory investigations are required beyond what you've already listed for a 10-year-old starting secukinumab for severe psoriasis vulgaris.
Current Standard of Care
The investigations you've outlined align with the 2020 Joint AAD-NPF pediatric psoriasis guidelines 1. The FDA label for secukinumab (Cosentyx) emphasizes TB screening and monitoring for infections but does not mandate additional baseline testing beyond standard infectious disease screening 2.
Your Complete Baseline Panel Includes:
- Tuberculosis screening: Tuberculin skin test (PPD), QuantiFERON Gold, or T-Spot
- Chest radiograph: For TB evaluation
- Hepatitis panel: HBsAg, HBcAb (IgG), HCV antibody
- HIV screening: HIV 1/2 antibody
- Complete blood count with differential
- Renal function tests
- Liver function tests
- Lipid profile
- Clinical assessment for inflammatory bowel disease symptoms
Key Monitoring Considerations
Tuberculosis Screening Nuances
The 2020 guidelines specify that yearly TB testing is recommended for high-risk patients (those with TB exposure, travel history, or contact with active TB cases), but for average-risk pediatric patients, screening frequency is at the dermatologist's discretion 1. Unlike TNF-alpha inhibitors, IL-17A inhibitors like secukinumab carry lower TB reactivation risk 3.
Important caveat: QuantiFERON Gold can remain positive after latent TB treatment, so document baseline results carefully 1.
Hepatitis B Monitoring
While you're correctly screening for HBV, be aware that HBV reactivation can occur even with negative HBsAg if Anti-HBc IgG is positive 4. For patients with isolated Anti-HBc positivity (occult HBV), consider baseline HBV-DNA PCR and periodic monitoring during treatment, though this is not universally mandated 5, 4.
Inflammatory Bowel Disease Assessment
Your clinical screening for IBD symptoms is appropriate. Secukinumab carries a specific warning about new-onset or exacerbation of inflammatory bowel disease 2, 3. Document any history of abdominal pain, diarrhea, or bloody stools. No additional baseline colonoscopy or inflammatory markers are required unless symptoms are present.
What You Don't Need
Pregnancy Testing
Not applicable for your 10-year-old male patient, but document that children should be up-to-date on all non-live vaccines before starting secukinumab 2.
Baseline Immunoglobulin Levels
Not required—secukinumab does not cause hypogammaglobulinemia like some other immunosuppressants.
Baseline Candida Screening
Not indicated. While mild-to-moderate mucocutaneous candidiasis (oral/genital) is the most common infection with secukinumab, baseline screening is unnecessary 3, 6, 7.
Common Pitfalls to Avoid
Don't delay treatment for chest X-ray if TB screening is negative and the patient is asymptomatic—chest radiography is discretionary per guidelines 1.
Don't use secukinumab if active TB infection is present—this is an absolute contraindication 2.
Don't forget to document latex allergy status—the Sensoready pen and prefilled syringe needle caps contain latex 2.
Don't overlook growth parameters—the guidelines recommend monitoring growth in all pediatric patients on long-term systemic therapy 1.
Ongoing Monitoring After Initiation
Once treatment begins, no routine laboratory monitoring is required for secukinumab, unlike methotrexate or cyclosporine 1. Monitor clinically for:
- Signs of infection (most common: nasopharyngitis, upper respiratory infections, candidiasis) 6, 7
- New or worsening GI symptoms suggesting IBD
- Efficacy measures (PASI scores, quality of life assessments)
The safety profile through 236 weeks in pediatric patients shows nasopharyngitis (13.9 per 100 patient-years), headache (5.8), and tonsillitis (4.7) as the most common adverse events, with only 3 cases of Candida infections reported 7.